StockData

Gossamer Bio vs Verastem

GOSS and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GOSS and VSTM compare

Gossamer Bio is the larger company, worth 8.0 times as much as Verastem ($5.4B against $671M).

Verastem keeps more of each dollar of sales as profit, with a net margin of −232% compared with −235% at Gossamer Bio.

Verastem scores higher on the StockData Score (3 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGOSSVSTM
Size and price
Market cap$5.4B$671M
Share price$11.04$7.41
Change, 1 year−94.9%−1.9%
Change, 5 years−98.7%−77.0%
Beta (5Y)2.332.66
Employees161102
StockData Score
Total score13 (better)
Valuation score00
Growth score11
Performance score01 (better)
Health score01 (better)
Dividend score00
Valuation
P/S101×7.7× (better)
P/B–13.4×
FCF yield−3.0%–
Growth
Revenue growth (TTM)32.4%–
Revenue growth, 5Y average–−19.0%
Profitability
Operating margin−312%−183% (better)
Net margin−235%−232% (better)
FCF margin−305%–
Return on equity–−471%
Financial health
Interest coverage−15.2× (better)−108.3×
Current ratio0.532.25 (better)
Altman Z-score−15.26−7.37 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions0.98%109%
Held by insiders2.8%1.8%
Insider net buying, 12 months–−$816K
Superinvestors holding1–
Short interest, % of float0.28%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.